Plasma metastin levels are negatively correlated with insulin resistance and free androgens in women with polycystic ovary syndrome
|
|
- Letitia Doyle
- 5 years ago
- Views:
Transcription
1 POLYCYSTIC OVARY SYNDROME Plasma metastin levels are negatively correlated with insulin resistance and free androgens in women with polycystic ovary syndrome Dimitrios Panidis, Ph.D., a David Rousso, M.D., a George Koliakos, M.D., b Anargyros Kourtis, M.D., a Ilias Katsikis, M.D., a Dimitrios Farmakiotis, M.D., a Elissavet Votsi, M.D., a and Evanthia Diamanti-Kandarakis, M.D. c a Division of Endocrinology and Human Reproduction, Second Department of Obstetrics and Gynecology and b Department of Biochemistry, Medical School, Aristotle University of Thessaloniki, Thessaloniki; and c Endocrine Section of the First Department of Internal Medicine, Athens University School of Medicine, Athens, Greece Objective: This study was designed to: [1] measure, for the first time, metastin (kisspeptin) levels in women with polycystic ovary syndrome (PCOS), a condition associated with hypersecretion of LH and hyperandrogenemia; and [2] investigate the possible correlations between metastin and PCOS-related reproductive and metabolic disturbances. Design: Clinical study. Setting: University hospital. Patient(s): Twenty-eight obese and overweight (body mass index [BMI] 25 kg/m 2 ) women with PCOS, 28 normal weight (BMI 25 kg/m 2 ) women with the syndrome, and 13 obese and overweight controls (ovulatory women without clinical or biochemical hyperandrogenemia) were selected. Intervention(s): Blood samples were collected between day 3 and day 6 of a spontaneous bleeding episode in the PCOS groups and a menstrual cycle of the controls, at 9:00 AM, after an overnight fast. Main Outcome Measure(s): Circulating levels of LH, FSH, PRL, T, 4 -androstenedione (A), DHEAS, 17 - OH-P, sex hormone-binding globulin (SHBG), insulin, glucose, and metastin were measured. Result(s): Both normal weight women with PCOS and obese controls were less insulin resistant and had significantly higher metastin levels, compared to obese and overweight women with the syndrome. Plasma kisspeptin levels were negatively correlated with BMI, free androgen index, and indices of insulin resistance. Conclusion(s): These results indicate that metastin is negatively associated with free androgen levels. The PCOS-associated insulin resistance and consequent hyperinsulinemia probably contribute to this effect by [1] stimulating androgen synthesis by the polycystic ovary (PCO) and [2] suppressing SHBG production in the liver. (Fertil Steril 2006;85: by American Society for Reproductive Medicine.) Key Words: Metastin, kisspeptin, PCOS, obesity, insulin resistance Metastin is a 54-amino-acid peptide, which was first isolated from the human placenta in 2001 (1). It is encoded by the Kiss-1 gene, therefore, it is also known as Kiss-1 peptide (kisspeptin) (2 4). Metastin action is exerted by a trans-membrane G-protein-coupled receptor, named GPR54, AXOR12, or HoT7T175 (1, 5, 6). Kiss-1 expression has been associated with antimetastatic activity in malignant melanoma (4), breast (7), papillary thyroid (3), esophageal (8) and bladder (9) carcinoma. Furthermore, kisspeptin has also been found to suppress the invasion of human trophoblast cells (10), a process sharing common pathways with tumor metastasis (11 13). A possible physiological role of this peptide in the control of trophoblast growth into adjacent Received March 24, 2005; revised and accepted November 6, Reprint requests: Anargyros Kourtis, M.D., 2nd Department of Obstetrics and Gynecology, 45 Aristotelous Str, 55236, Panorama, Greece (FAX: ; argic@med.auth.gr). tissues could also account for the dramatic increase of plasma metastin levels in pregnancy (14). Intriguingly, loss of Kiss-1 function is associated with hypogonadotropic hypogonadism in humans (15) and in animal models (16, 17). Administration of the Kiss-1 peptide (metastin/kisspeptin) has been shown to induce maturation of the female reproductive system and precocious puberty in rodents (18). Moreover, there is strong evidence that metastin exerts these effects by stimulating GnRH release from the hypothalamus, and, as a consequence, pituitary LH secretion (19 22). It is also interesting that a negative feedback loop might also exist, as kisspeptin has been reported to be down-regulated by sex steroids (23). The polycystic ovary syndrome (PCOS) is a common heterogeneous disorder of women of reproductive age, and the most frequent cause of hyperandrogenism combined with 1778 Fertility and Sterility Vol. 85, No. 6, June /06/$32.00 Copyright 2006 American Society for Reproductive Medicine, Published by Elsevier Inc. doi: /j.fertnstert
2 anovulatory infertility (24, 25). Its complex pathogenesis involves [1] hypothalamic pituitary disturbances in gonadotropin secretion, specifically increased LH levels (26, 27); [2] increased resistance to insulin (28) and compensatory hyperinsulinemia, which has been associated with enhanced androgen production (29) and reduced synthesis of sex hormone-binding globulin (SHBG) (30); and [3] disturbed gonadal steroidogenesis (31). Given the complex relationship between the novel peptide metastin and the hypothalamic pituitary gonadal axis, the present study was designed to: [1] measure metastin levels in women with PCOS, a condition associated with aberrant gonadotropin secretion and hyperandrogenemia; and [2] investigate the possible correlations between kisspeptin and PCOS-related reproductive and metabolic disturbances. Hormonal and Biochemical Measurements and Calculations Blood samples were collected between day 3 and day 6 of a spontaneous bleeding episode in the PCOS groups and a menstrual cycle of the controls, at 9:00 AM, after an overnight fast. In all women, basal serum levels of FSH, LH, T, 4 -androstenedione (A), and DHEAS were measured. Fasting concentrations of PRL, 17 -OH-P, sex hormone-binding globulin (SHBG), glucose, insulin, and metastin were also measured. Free androgen index (FAI) was calculated according to the equation: T (nmol/l) 100/SHBG (nmol/l) (34). Homeostatic model assessment insulin resistance (HoMA-IR) was derived from the equation: Glucose (mmol/l) Insulin ( IU/mL)/22.5 (35). The glucose-to-insulin ratio was also calculated as a reliable index of insulin resistance (36). Hyperandrogenemia was defined as T levels 60 ng/ml. This value was derived from the mean value 2SD of 100 control women. On the same day that blood samples were collected, transvaginal ultrasonographic evaluation was performed. MATERIALS AND METHODS Subjects Fifty-six women with PCOS, aged years, were recruited from the outpatient endocrine infirmary of our clinic, with at least one of the following signs: oligomenorrhea, fertility problem, hirsutism, acne, or male pattern alopecia. Diagnosis of PCOS was based on the presence of chronic anovulation (less than six cycles in 12 months) and hyperandrogenemia. Other common causes of hyperandrogenism or menstrual disorders (prolactinoma, congenital adrenal hyperplasia, Cushing syndrome, and virilizing ovarian or adrenal tumors) were excluded, in accord with the criteria proposed in 1990 by the National Institutes of Health National Institute of Child Health and Human Development (NIH- NICHHD) (32), and revised in 2003 by the Rotterdam ESHRE/ASRM-sponsored PCOS Consensus Workshop Group (33). Women with PCOS were further divided into two groups, based on body mass index (BMI) values: obese and overweight (BMI 25 kg/m 2 )(n 28) and normal weight (BMI 25 kg/m 2 ) women with the syndrome (n 28). Thirteen obese and overweight healthy women, aged years, volunteered as controls. All controls had normal ovulating cycles (28 2 days, blood P levels 10 ng/ml in two consequent cycles), and no signs of hyperandrogenism. None of the women studied had galactorrhea, or systemic disease that could affect their reproductive physiology. Furthermore, no woman reported use of any medication that could interfere with the normal function of the hypothalamic pituitary gonadal axis, during the past 6 months. Informed consent was obtained from all 69 women and the study was approved by the local ethical committee. Assay Methods Plasma glucose concentrations were measured with the glucose oxidase technique using an auto-analyzer (Roche/Hitachi 902; Roche Diagnostics GmBH, Manheim, Germany). LH, FSH, PRL, androgen, and 17 -OH-P levels were measured with the RIA method, whereas SHBG levels were measured with the IRMA method, using commercial kits (FSH: Radioisotopic Kit, Nichols Institute Diagnostics, San Juan Capistrano, CA; LH: Radioisotopic Kit, Nichols Institute Diagnostics; PRL: Radioisotopic Kit, Nichols Institute Diagnostics; T: Radioisotopic Kit, Diagnostic Systems Laboratories, Webster, TX; 4 A: Radioisotopic Kit, Diagnostic Systems Laboratories; DHEAS: Radioisotopic Kit, Diagnostic Systems Laboratories; 17 -OHP: Radioisotopic Kit, Diagnostic Systems Laboratories; SHBG: Immunoradiometric Assay (IRMA) Kit, Diagnostic Systems Laboratories). Serum insulin levels were measured by enzyme immunoassay (ELISA Kit, Mercodia AB, Uppsala, Sweden). Metastin levels were also measured with an enzyme-linked immunoassay kit (ELISA kit, Phoenix Pharmaceuticals Inc., Belmond, CA), after extraction with Phoenix Peptide sep-columns (RK-Sepcol-2). An intra-assay variation of 4.5% was observed. Statistical Analyses Values are presented as mean standard error for mean (SEM). The Kolmogorov-Smirnov test was used to test the normality of distribution. Comparison of means between women with PCOS and controls was performed with the Mann-Whitney U test for non-normal values. Comparisons between the three groups were performed with multivariate general linear model-based one-way analysis of variance (ANOVA), after log-transformation of non-normal values. Post-hoc analysis was performed with Dunnette s T3 test. Calculation of the Spearman coefficient was used to assess the correlation of plasma kisspeptin to each parameter. All analyses were performed by SPSS software (v.13.0 SPSS, Inc., Chicago, IL). The level of statistical significance was set at 5%. Fertility and Sterility 1779
3 TABLE 1 Anthropometric, hormonal, and metabolic features of the women studied (mean SEM, statistical significance). PCOS BMI >25 PCOS BMI <25 Controls BMI >25 P value (ANOVA) No of women (n) Age (y) ns BMI (kg/m 2 ) a b.001 W/H a FSH (miu/ml) ns LH (miu/ml) ab.001 PRL (ng/ml) ns T (ng/dl) ab.001 FAI a ab A (ng/ml) ab.001 DHEA-S ( g/ml) OH-progesterone (ng/ml) ab.001 SHBG (nmol/l) a a.001 Glucose (mg/dl) ns Insulin ( IU/mL) a a.001 HoMA-IR a a.001 Glucose-to-insulin ratio a a.001 Metastin (fmol/ml) a See text for abbreviations. a Post-hoc P.05 vs obese and overweight women with PCOS. b Post-hoc P.05 vs normal weight women with PCOS. RESULTS Basic anthropometric, hormonal, and metabolic features of the women studied are summarized in Table 1. No significant difference in age was observed. Obese and overweight women with PCOS had significantly higher BMI and waistto-hip ratio than normal weight women with the syndrome (P.001). Obese and overweight controls had significantly higher BMI, compared to lean women with PCOS, but the difference in the waist-to-hip ratio was nonsignificant (P.095). No difference in BMI or waist-to-hip ratio was observed between the two groups with BMI 25 kg/m 2. The LH levels were significantly higher in both groups of women with PCOS, compared to controls (P.001). Normal weight women with PCOS had higher LH levels, compared to obese and overweight women with the syndrome, but not significantly. No significant difference was found in FSH or PRL levels between the three groups. Women with PCOS had higher T, A, 17 -OH-P levels and FAI values, compared to controls (P.001). No difference in androgen levels was observed between the two groups of women with PCOS. Normal weight women with the syndrome had significantly lower FAI values, and higher SHBG levels, compared to women with PCOS and BMI 25 kg/m 2 (P.001). Obese and overweight women with PCOS also had significantly lower SHBG levels, compared to controls (P.001); no difference in SHBG levels was observed between the two groups of lean women. No difference in fasting glucose levels was observed between the three groups. Insulin levels and HoMA-IR values were significantly higher, and the glucose-to-insulin ratio was significantly lower in obese and overweight women with PCOS, compared to lean women with the syndrome (P.001) and obese/overweight controls (P.05). No significant difference was observed between the latter two groups. Metastin levels were lower in women with PCOS ( fmol/ml), compared to controls ( fmol/ml), but not significantly (Fig. 1).However, when women with PCOS were further divided, based on BMI values, a significant difference emerged (P.05). Specifically, metastin levels were significantly higher in normal weight women with PCOS (Post-hoc P.05), compared to obese and overweight women with the syndrome. No significant difference was found between the two groups of obese and overweight women, neither between the control group and obese/overweight women with PCOS, although kisspeptin levels were higher in controls (Fig. 2) Panidis et al. Metastin in PCOS Vol. 85, No. 6, June 2006
4 FIGURE 1 Plasma metastin levels of all women with polycystic ovary syndrome (PCOS) and controls (mean SEM). FIGURE 3 Scatter-plot diagram of plasma metastin levels vs. free androgen index (FAI); r 0.255, P.05. PCOS polycystic ovary syndrome. FIGURE 2 Plasma metastin levels of obese or overweight women with polycystic ovary syndrome (PCOS), normal weight women with PCOS, and controls (mean SEM); *P.05 vs. obese and overweight women with PCOS. Metastin levels were found to be negatively correlated with BMI (r 0.238, P.05), fasting insulin levels (r 0.308, P.05), FAI (r 0.255, P.05) (Fig. 3), and HoMA-IR values (r 0.238, P.05) and positively correlated with SHBG levels (r 0.249, P.05) and the glucose-to-insulin ratio (r 0.338, P.005) (Fig. 4). DISCUSSION In the present study, plasma concentrations of metastin (kisspeptin), a novel peptide with putative antimetastatic and endocrine properties (1 9), were measured, for the first time, in women with PCOS. Apparently this peptide is also involved in the complex mechanisms that regulate hypothalamic pituitary gonadal function and reproductive physiology (14 18). Specifically, metastin has been recently associated with increased GnRHinduced secretion of LH (19 22). Because women with PCOS demonstrate higher LH levels, compared to ovulatory women without the syndrome (24 26), one would expect kisspeptin levels to be significantly increased in the former. Nevertheless, in our study, no such difference was observed (Table 1, Fig. 1), although LH levels were significantly higher in both groups of women with PCOS, compared to controls (Table 1). Moreover, no significant correlation between plasma metastin and LH levels was observed. On that basis metastin does not seem to be directly involved in the increased LH secretion observed in women Fertility and Sterility 1781
5 FIGURE 4 Scatter-plot diagram of plasma metastin levels vs. glucose-to-insulin ratio; r 0.338, P.005. PCOS polycystic ovary syndrome. values), compared to normal weight women with the syndrome and controls (Table 1). Moreover, plasma kisspeptin levels were significantly correlated with FAI (Fig. 3). Because it has been reported that metastin and gonadal steroids are inversely correlated (23), we conclude that the increase in free androgen levels, as a result of insulin resistance, is associated with a relative decrease in circulating kispeptin levels. In summary, the present findings indicate that metastin, although not directly involved in PCOS-associated LH hypersecretion, is negatively correlated with insulin resistance and increased free androgen levels, which are prominent features of the syndrome. It seems improbable that metastin (kisspeptin) can be a single cause of PCOS-associated reproductive or metabolic abnormalities. However, it could be involved in the interaction between gonadotropin secretion and the negative feedback influence of sex steroids. with PCOS. It should be noted that most data on the interactions between gonadotropin production and this novel hormone are, so far, obtained from rodents (16 22), whereas studies of plasma kisspeptin in humans are rather scarce (14, 15). It is, therefore, possible that different pathways determine the relationship between metastin and human physiology of reproduction. Interestingly, when women with PCOS were further divided, based on BMI values, obese and overweight women with the syndrome had significantly lower kisspeptin levels compared to normal weight women with the syndrome (Fig. 2). In the present study, the number of control women was relatively small, and no lean healthy volunteers were involved. Therefore, it is too soon to draw definite conclusions. It should be noted that metastin levels were significantly and inversely correlated with all indices of insulin resistance (Figs. 3 and 4) and women with PCOS and BMI 25 kg/m 2 were more insulin-resistant, compared to women with PCOS and BMI 25 kg/m 2, and controls with BMI 25 kg/m 2. From these results, it can be inferred that insulin resistance is linked to a significant decrease in plasma metastin levels. The PCOS-associated insulin resistance with compensatory hyperinsulinemia have been shown to increase free androgen levels by stimulating androgen synthesis in the PCO (29) and also by suppressing SHBG production in the liver (30). In our study, women with PCOS and BMI 25 kg/m 2 had significantly higher free androgen levels (FAI REFERENCES 1. Ohtaki T, Shintani Y, Honda S, Matsumoto H, Hori A, Kanehashi K, et al. Metastasis suppressor gene KiSS-1 encodes peptide ligand of a G-protein-coupled receptor. Nature 2001;411: Hori A, Honda S, Asada M, Ohtaki T, Oda K, Watanabe T, et al. Metastin suppresses the motility and growth of CHO cells transfected with its receptor. Biochem Biophys Res Commun 2001;286: Ringel MD, Hardy E, Bernet VJ, Burch HB, Schuppert F, Burman KD, et al. Metastin receptor is overexpressed in papillary thyroid cancer and activates MAP kinase in thyroid cancer cells. J Clin Endocrinol Metab 2002;87: Lee JH, Miele ME, Hicks DJ, Phillips KK, Trent JM, Weissman BE, et al. KiSS-1, a novel human malignant melanoma metastasis-suppressor gene. J Natl Cancer Inst 1996;88: Kotani M, Detheux M, Vandenbogaerde A, Communi D, Vanderwinden JM, et al. The metastasis suppressor gene KiSS-1 encodes kisspeptins, the natural ligands of the orphan G protein-coupled receptor GPR54. J Biol Chem 2001;276: Muir AI, Chamberlain L, Elshourbagy NA, Michalovich D, Moore DJ, Calamari A, et al. AXOR12, a novel human G protein-coupled receptor, activated by the peptide KiSS-1. J Biol Chem 2001;276: Lee JH, Welch DR. Suppression of metastasis in human breast carcinoma MDA-MB-435 cells after transfection with the metastasis suppressor gene, KiSS-1. Cancer Res 1997;57: Ikeguchi M, Yamaguchi K, Kaibara N. Clinical significance of the loss of KiSS-1 and orphan G-protein-coupled receptor (hot7t175) gene expression in esophageal squamous cell carcinoma. Clin Cancer Res 2004;10: Sanchez-Carbayo M, Capodieci P, Cordon-Cardo C. Tumor suppressor role of KiSS-1 in bladder cancer: loss of KiSS-1 expression is associated with bladder cancer progression and clinical outcome. Am J Pathol 2003;162: Bilban M, Ghaffari-Tabrizi N, Hintermann E, Bauer S, Molzer S, Zoratti C, et al. Kisspeptin-10, a KiSS-1/metastin-derived decapeptide, is a physiological invasion inhibitor of primary human trophoblasts. J Cell Sci 2004;117: McMaster MT, Bass KE, Fisher SJ. Human trophoblast invasion. Autocrine control and paracrine modulation. Ann NY Acad Sci 1994; 734: Murray MJ, Lessey BA. Embryo implantation and tumor metastasis: common pathways of invasion and angiogenesis. Semin Reprod Endocrinol 1999;17: Bischof P, Meisser A, Campana A. Paracrine and autocrine regulators of trophoblast invasion a review. Placenta 2000;21:S55 S Panidis et al. Metastin in PCOS Vol. 85, No. 6, June 2006
6 14. Horikoshi Y, Matsumoto H, Takatsu Y, Ohtaki T, Kitada C, Usuki S, et al. Dramatic elevation of plasma metastin concentrations in human pregnancy: metastin as a novel placenta-derived hormone in humans. J Clin Endocrinol Metab 2003;88: de Roux N, Genin E, Carel JC, Matsuda F, Chaussain JL, Milgrom E. Hypogonadotropic hypogonadism due to loss of function of the KiSS1- derived peptide receptor GPR54. Proc Natl Acad Sci USA 2003;100: Seminara SB, Messager S, Chatzidaki EE, Thresher RR, Acierno JS, Shagoury JK, et al. The GPR54 gene as a regulator of puberty. N Engl J Med 2003;349: Funes S, Hendrick JA, Vassileva G, Markowitz L, Abbondanzo S, Golovko A, et al. The KiSS-1 receptor GPR54 is essential for the development of the murine reproductive system. Biochem Biophys Res Commun 2003;312: Navarro VM, Fernandez-Fernandez R, Castellano JM, Roa J, Mayen A, Barreiro ML, et al. Advanced vaginal opening and precocious activation of the reproductive axis by KiSS-1 peptide, the endogenous ligand of GPR54. J Physiol 2004;561: Gottsch ML, Cunningham MJ, Smith JT, Popa SM, Acohido BV, Crowley WF, et al. A role for kisspeptins in the regulation of gonadotropin secretion in the mouse. Endocrinology 2004;145: Matsui H, Takatsu Y, Kumano S, Matsumoto H, Ohtaki T. Peripheral administration of metastin induces marked gonadotropin release and ovulation in the rat. Biochem Biophys Res Commun 2004;320: Navarro VM, Castellano JM, Fernandez-Fernandez R, Barreiro ML, Roa J, Sanchez-Criado JE, et al. Developmental and hormonally regulated messenger ribonucleic acid expression of KiSS-1 and its putative receptor GPR54 in rat hypothalamus and potent LH releasing activity of KiSS-1 peptide. Endocrinology 2004;145: Navarro VM, Castellano JM, Fernandez-Fernandez R, Tovar S, Roa J, Mayen A, et al. Characterization of the potent LH releasing activity of KiSS-1 peptide, the natural ligand of GPR54. Endocrinology 2005;146: Colledge WH. GPR54 and puberty. Trends Endocrinol Metab 2004;15: Diamanti-Kandarakis E, Dunaif A. New perspectives in polycystic ovary syndrome. Trends Endocrinol Metab 1996;7: Diamanti-Kandarakis E, Kouli C, Bergiele A, Filandra F, Tsianateli T, Spina G, et al. A survey of the polycystic ovary syndrome in the Greek island of Lesbos: hormonal and metabolic profile. J Clin Endocrinol Metab 1999;84: Panidis D, Koliakos G, Kourtis A, Farmakiotis D, Mouslech T, Rousso D. Serum resistin levels in women with polycystic ovary syndrome. Fertil Steril 2004;81: Panidis D, Farmakiotis D, Rousso D. Katsikis I, Kourtis A, Diamanti- Kandarakis E, Serum luteinizing hormone levels are markedly increased and significantly correlated with 4 -androstenedione levels in lean women with polycystic ovary syndrome. Fertil Steril 2005;84: Goodarzi MO, Korenman SG. The importance of insulin resistance in polycystic ovary syndrome. Fertil Steril 2003;80: Poretsky L, Cataldo NA, Rosenwaks Z, Giudice LC. The insulin-related ovarian regulatory system in health and disease. Endocr Rev 1999;20: Nestler JE, Powers LP, Matt DW, Steingold KA, Plymate SR, Rittmaster RS, et al. A direct effect of hyperinsulinemia on serum sex hormonebinding globulin levels in obese women with the polycystic ovary syndrome. J Clin Endocrinol Metab 1991;72: Diamanti-Kandarakis E, Bartzis MI, Zapanti ED, Spina CG, Filandra FA, Tsianateli TC, et al. Polymorphism TC (-34 bp) of gene CYP17 promoter in Greek patients with polycystic ovary syndrome. Fertil Steril 1999;71: Zawadski JK, Dunaif A. Diagnostic criteria for polycystic ovary syndrome: towards a rational approach. In: Dunaif A, Givens JR, Haseltine FP, Merriam GE, eds. Polycystic ovary syndrome. Hershman SM, series ed. Current issues in endocrinology and metabolism. Boston: Blackwell Scientific Publications, 1992: The Rotterdam ESHRE/ASRM-sponsored PCOS Consensus Workshop Group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS). Hum Reprod 2004;19: Morley JE, Patrick P, Perry HM III. Evaluation of assays available to measure free testosterone. Metabolism 2002;5: Matthews D, Hosker J, Rudenski A, Naylor B, Treacher D, Turner R. Homeostasis model assessment: insulin resistance and -cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985;28: Legro RS, Finegood D, Dunaif A. A fasting glucose to insulin ratio is a useful measure of insulin sensitivity in women with polycystic ovary syndrome. J Clin Endocrinol Metab 1998;83: Fertility and Sterility 1783
rs4889 polymorphism in KISS1 gene, its effect on polycystic ovary syndrome development and anthropometric and hormonal parameters in Saudi women
Albalawi et al. Journal of Biomedical Science (2018) 25:50 https://doi.org/10.1186/s12929-018-0452-2 RESEARCH Open Access rs4889 polymorphism in KISS1 gene, its effect on polycystic ovary syndrome development
More informationROLE OF HORMONAL ASSAY IN DIAGNOSING PCOD DR GAANA SREENIVAS (JSS,MYSURU)
ROLE OF HORMONAL ASSAY IN DIAGNOSING PCOD DR GAANA SREENIVAS (JSS,MYSURU) In 1935, Stein and Leventhal described 7 women with bilateral enlarged PCO, amenorrhea or irregular menses, infertility and masculinizing
More informationPolycystic Ovary Syndrome HEATHER BURKS, MD OU PHYSICIANS REPRODUCTIVE MEDICINE SEPTEMBER 21, 2018
Polycystic Ovary Syndrome HEATHER BURKS, MD OU PHYSICIANS REPRODUCTIVE MEDICINE SEPTEMBER 21, 2018 Learning Objectives At the conclusion of this lecture, learners should: 1) Know the various diagnostic
More informationDetermining the insulin resistance rate in Polycystic Ovary Syndrome patients (PCOs)
Abstract: Determining the insulin resistance rate in Polycystic Ovary Syndrome patients (PCOs) Ashraf Olabi, Ghena Alqotini College of medicine, Aleppo University Hospital Obstetrics and Gynacology, Syria.
More informationSerum resistin levels in women with polycystic ovary syndrome
FERTILITY AND STERILITY VOL. 81, NO. 2, FEBRUARY 2004 Copyright 2004 American Society for Reproductive Medicine Published by Elsevier Inc. Printed on acid-free paper in U.S.A. Serum resistin levels in
More informationCan Sex hormone Binding Globulin Considered as a Predictor of Response to Pharmacological Treatment in Women with Polycystic Ovary Syndrome?
www.ijpm.in www.ijpm.ir Can Sex hormone Binding Globulin Considered as a Predictor of Response to Pharmacological Treatment in Women with Polycystic Ovary Syndrome? Ferdous Mehrabian, Maryam Afghahi Department
More informationS. AMH in PCOS Research Insights beyond a Diagnostic Marker
S. AMH in PCOS Research Insights beyond a Diagnostic Marker Dr. Anushree D. Patil, MD. DGO Scientist - D National Institute for Research in Reproductive Health (Indian Council of Medical Research) (Dr.
More informationClinical and endocrine characteristics of the main polycystic ovary syndrome phenotypes
POLYCYSTIC OVARY SYNDROME Clinical and endocrine characteristics of the main polycystic ovary syndrome phenotypes Ettore Guastella, M.D., a Rosa Alba Longo, M.D., b and Enrico Carmina, M.D. b a Department
More informationInsulin resistance and endocrine characteristics of the different phenotypes of polycystic ovary syndrome: a prospective study
Human Reproduction, Vol.0, No.0 pp. 1 9, 2011 doi:10.1093/humrep/der418 Hum. Reprod. Advance Access published December 5, 2011 ORIGINAL ARTICLE Reproductive endocrinology Insulin resistance and endocrine
More informationCase Questions. Polycystic Ovarian Syndrome: Treatment Goals and Options. Differential Diagnosis of Hyperandrogenic Anovulation
Polycystic Ovarian Syndrome: Treatment Goals and Options Marc Cornier, MD Division of Endocrinology, Metabolism and Diabetes Colorado Center for Health and Wellness University of Colorado School of Medicine
More informationReproductive FSH. Analyte Information
Reproductive FSH Analyte Information 1 Follicle-stimulating hormone Introduction Follicle-stimulating hormone (FSH, also known as follitropin) is a glycoprotein hormone secreted by the anterior pituitary
More informationPrevalence of polycystic ovarian syndrome in the Buraimi region of Oman
Original Article Brunei Int Med J. 2012; 8 (5): 248-252 Prevalence of polycystic ovarian syndrome in the Buraimi region of Oman Usha VARGHESE 1 and Shaji VARUGHESE 2, 1 Department of Internal Medicine
More informationEnzyme linked immunosorbent assay (ELSA) investigation for Human Kisspeptin and progesterone Levels in female having regular menstrual cycle
Original Article Enzyme linked immunosorbent assay (ELSA) investigation for Human Kisspeptin and progesterone Levels in female having regular menstrual cycle * MSc, PhD Fac Med Baghdad 2011; Vol. 53, No.
More informationCurrent Highlights The role of kisspeptin signalling in control of reproduction in genetically similar species
Current Highlights The role of kisspeptin signalling in control of reproduction in genetically similar species Amir Babiker (1), Adnan Al Shaikh (2) (1) King Saud University Medical City and King Saud
More informationASSOCIATION OF INSULIN RESISTANCE AND SERUM 25 OH VITAMIN-D IN INDIAN WOMEN WITH POLYCYSTIC OVARY SYNDROME
RESEARCH ARTICLE ASSOCIATION OF INSULIN RESISTANCE AND SERUM 25 OH VITAMIN-D IN INDIAN WOMEN WITH POLYCYSTIC OVARY SYNDROME Amar Nagesh Kumar 1, Jupalle Nagaiah Naidu 2, Uppala Satyanarayana 3, Medabalmi
More informationInfertility Treatment in Polycystic Ovary Syndrome: Lifestyle Interventions, Medications and Surgery
Macut D, Pfeifer M, Yildiz BO, Diamanti-Kandarakis E (eds): Polycystic Ovary Syndrome. Novel Insights into Causes Infertility Treatment in Polycystic Ovary Syndrome: Lifestyle Interventions, Medications
More informationEffect of troglitazone on endocrine and ovulatory performance in women with insulin resistance related polycystic ovary syndrome
FERTILITY AND STERILITY VOL. 71, NO. 2, FEBRUARY 1999 Copyright 1999 American Society for Reproductive Medicine Published by Elsevier Science Inc. Printed on acid-free paper in U.S.A. Effect of troglitazone
More informationInvestigation of adrenal functions in patients with idiopathic hyperandrogenemia
European Journal of Endocrinology (26) 155 37 311 ISSN 84-4643 CLINICAL STUDY Investigation of adrenal functions in patients with idiopathic hyperandrogenemia Hulusi Atmaca, Fatih Tanriverdi 1, Kursad
More informationOverview of Reproductive Endocrinology
Overview of Reproductive Endocrinology I have no conflicts of interest to report. Maria Yialamas, MD Female Hypothalamic--Gonadal Axis 15 4 Hormone Secretion in the Normal Menstrual Cycle LH FSH E2, Progesterone,
More informationX/06/$15.00/0 The Journal of Clinical Endocrinology & Metabolism 91(1):2 6 Copyright 2006 by The Endocrine Society doi: /jc.
0021-972X/06/$15.00/0 The Journal of Clinical Endocrinology & Metabolism 91(1):2 6 Printed in U.S.A. Copyright 2006 by The Endocrine Society doi: 10.1210/jc.2005-1457 EXTENSIVE CLINICAL EXPERIENCE Relative
More informationPCOS and Obesity DUB is better treated by OCPs
PCOS and Obesity DUB is better treated by OCPs Dr. Ritu Joshi Senior consultant Fortis escorts Hospital, Jaipur Chairperson Family welfare com. FOGSI (20092012) Vice President FOGSI 2014 Introduction One
More informationIntroduction. Original Article
Iran J Reprod Med Vol. 10. No. 4. pp: 307-314, July 2012 Original Article Correlation of biochemical markers and clinical signs of hyperandrogenism in women with polycystic ovary syndrome (PCOS) and women
More informationPolycystic Ovary Syndrome
Polycystic Ovary Syndrome Definition: the diagnostic criteria Evidence of hyperandrogenism, biochemical &/or clinical (hirsutism, acne & male pattern baldness). Ovulatory dysfunction; amenorrhoea; oligomenorrhoea
More informationThe prevalence of polycystic ovary syndrome in Iranian women based on different diagnostic criteria
Prace oryginalne/original papers Endokrynologia Polska/Polish Journal of Endocrinology Tom/Volume 62; Numer/Number 3/2011 ISSN 0423 104X The prevalence of polycystic ovary syndrome in Iranian women based
More informationNitasha Garg 1 Harkiran Kaur Khaira. About the Author
https://doi.org/10.1007/s13224-017-1082-4 ORIGINAL ARTICLE A Comparative Study on Quantitative Assessment of Blood Flow and Vascularization in Polycystic Ovary Syndrome Patients and Normal Women Using
More informationWEIGHT CHANGE AND ANDROGEN LEVELS DURING CONTRACEPTIVE TREATMENT OF WOMEN AFFECTED BY POLYCYSTIC OVARY
ENDOCRINE REGULATIONS, VOL. 40, 119-123, 2006 119 WEIGHT CHANGE AND ANDROGEN LEVELS DURING CONTRACEPTIVE TREATMENT OF WOMEN AFFECTED BY POLYCYSTIC OVARY J. VRBIKOVA, K. DVORAKOVA, M. HILL, L. STARKA Institute
More informationPolycystic Ovary Syndrome Therapy Dr. Pilar Vigil MD, PhD, FACOG
Polycystic Ovary Syndrome Therapy Dr. Pilar Vigil MD, PhD, FACOG What is an ovulatory dysfunction? Mrs. Susana Godoy, Nurse-Midwife San José, Costa Rica Abril 2018 PONTIFICIA UNIVERSIDAD CATÓLICA DE CHILE
More information12/13/2017. Important references for PCOS. Polycystic Ovarian Syndrome (PCOS) for the Family Physician. 35 year old obese woman
Polycystic Ovarian Syndrome (PCOS) for the Family Physician Barbara S. Apgar MD, MS Professor or Family Medicine University of Michigan Ann Arbor, Michigan Important references for PCOS Endocrine Society
More informationPOLYCYSTIC ovary syndrome (PCOS) appears to be a
0021-972X/99/$03.00/0 Vol. 84, No. 11 The Journal of Clinical Endocrinology & Metabolism Printed in U.S.A. Copyright 1999 by The Endocrine Society A Survey of the Polycystic Ovary Syndrome in the Greek
More informationOutlook PCOS: a diagnostic challenge
RBMOnline - Vol 8. No 6. 2004 644-648 Reproductive BioMedicine Online; www.rbmonline.com/article/1274 on web 5 April 2004 Outlook PCOS: a diagnostic challenge Dr Ricardo Azziz Dr Azziz is currently Chairman
More informationPolycystic Ovarian Syndrome (PCOS) LOGO
Polycystic Ovarian Syndrome (PCOS) Ma qianhong Ob/Gyn Department LOGO Contents Epidemiology and Definition Pathophysiology, Endocrinological Features Diagnostic Criteria Treatment Prognosis Introduction
More informationPolycystic Ovarian Syndrome: Diagnosis, Preconceptional Management and Health Risks
Polycystic Ovarian Syndrome: Diagnosis, Preconceptional Management and Health Risks Kate D. Schoyer, M.D. May 6, 2016 Objectives To review how to make the diagnosis of Polycystic Ovarian Syndrome (PCOS)
More informationWHY NEW DIAGNOSTIC CRITERIA FOR DIFFERENT PCOS PHENOTYPES ARE URGENTLY NEEDED
WHY NEW DIAGNOSTIC CRITERIA FOR DIFFERENT PCOS PHENOTYPES ARE URGENTLY NEEDED Ricardo Azziz, M.D., M.P.H., M.B.A. Chief Officer of Academic Health & Hospital Affairs State University of New York (SUNY)
More informationThe contributions of oestrogen and growth factors to increased adrenal androgen secretion in polycystic ovary syndrome
Human Reproduction vol.14 no.2 pp.307 311, 1999 The contributions of oestrogen and growth factors to increased adrenal androgen secretion in polycystic ovary syndrome E.Carmina 1, F.Gonzalez 2, A.Vidali
More informationInternational Journal of Health Sciences and Research ISSN:
International Journal of Health Sciences and Research www.ijhsr.org ISSN: 2249-9571 Original Research Article A Study on Assessment of Testosterone, Insulin Resistance and HbA1c in Women with Polycystic
More informationPolycystic Ovary Syndrome (PCOS):
Polycystic Ovary Syndrome (PCOS): Current diagnosis and treatment Anatte E. Karmon, MD Disclosures- Anatte Karmon, MD No financial relationships to disclose 2 Objectives At the end of this presentation,
More informationAntim ullerian hormone and polycystic ovary syndrome
Antim ullerian hormone and polycystic ovary syndrome Yi-Hui Lin, M.D., a Wan-Chun Chiu, Ph.D., c Chien-Hua Wu, Ph.D., b,e Chii-Ruey Tzeng, M.D., d Chun-Sen Hsu, M.D., a and Ming-I Hsu, M.D. a a Department
More informationCREATING A PCOS TREATMENT PLAN. Ricardo Azziz, M.D., M.P.H., M.B.A. Georgia Regents University
CREATING A PCOS TREATMENT PLAN Ricardo Azziz, M.D., M.P.H., M.B.A. Georgia Regents University PCOS: CREATING A TREATMENT PLAN Good treatment plans are based on sound and complete evaluations History of
More informationMETABOLIC RISK MARKERS IN WOMEN WITH POLYCYSTIC OVARIAN MORPHOLOGY
Vuk Vrhovac University Clinic Dugi dol 4a, HR-10000 Zagreb, Croatia Original Research Article Received: February 18, 2010 Accepted: March 3, 2010 METABOLIC RISK MARKERS IN WOMEN WITH POLYCYSTIC OVARIAN
More informationmetabolic characteristics of the polycystic ovary syndrome
Page 1 of 32 Accepted Preprint first posted on 29 October 2012 as Manuscript EJE-12-0655 1 1 2 Association between menstrual cycle irregularities and endocrine and metabolic characteristics of the polycystic
More informationSerum Kisspeptin Levels in Korean Girls with Central Precocious Puberty
ORIGINAL ARTICLE Pediatrics DOI: 10.3346/jkms.2011.26.7.927 J Korean Med Sci 2011; 26: 927-931 Serum Kisspeptin Levels in Korean Girls with Central Precocious Puberty Young Jun Rhie 1,2, Kee Hyoung Lee
More informationPolycystic Ovarian Syndrome: Diagnosis, Preconceptional Management and Health Risks. Kate D. Schoyer, M.D. May 6, 2016
Polycystic Ovarian Syndrome: Diagnosis, Preconceptional Management and Health Risks Kate D. Schoyer, M.D. May 6, 2016 Objectives To review how to make the diagnosis of Polycystic Ovarian Syndrome (PCOS)
More information3. Metformin therapy for PCOS
1. Introduction The key clinical features of polycystic ovary syndrome (PCOS) are hyperandrogenism (hirsutism, acne, alopecia) and menstrual irregularity with associated anovulatory infertility. 1 The
More informationOriginal Investigation. 94 Endocrine Oncology and Metabolism. Jovanovska et al
Original Investigation Sensitivity and specificity of anti-mülerian hormone in the diagnosis of polycystic ovary syndrome in a macedonian population of women of reproductive age: a cross-sectional study
More informationObjectives 1. Be able to describe the classic presentation and diagnostic criteria 2. Be able to explain long-term health concerns associated with the diagnosis 3. Understand what basic treatment options
More informationAchieving Pregnancy: Obesity and Infertility. Jordan Vaughan, MSN, APN, WHNP-BC Women s Health Nurse Practitioner Nashville Fertility Center
Achieving Pregnancy: Obesity and Infertility Jordan Vaughan, MSN, APN, WHNP-BC Women s Health Nurse Practitioner Nashville Fertility Center Disclosures Speakers Bureau EMD Serono Board of Directors Nurse
More informationEndocrine part one. Presented by Dr. Mohammad Saadeh The requirements for the Clinical Chemistry Philadelphia University Faculty of pharmacy
Endocrine part one Presented by Dr. Mohammad Saadeh The requirements for the Clinical Chemistry Philadelphia University Faculty of pharmacy HORMONES Hormones are chemicals released by a cell or a gland
More informationPOLYCYSTIC OVARY SYNDROME (PCOS) is a genetically
0021-972X/04/$15.00/0 The Journal of Clinical Endocrinology & Metabolism 89(6):2745 2749 Printed in U.S.A. Copyright 2004 by The Endocrine Society doi: 10.1210/jc.2003-032046 The Prevalence and Features
More informationJMSCR Vol 05 Issue 05 Page May 2017
www.jmscr.igmpublication.org Impact Factor 5.84 Index Copernicus Value: 83.27 ISSN (e)-2347-176x ISSN (p) 2455-0450 DOI: https://dx.doi.org/10.18535/jmscr/v5i5.14 Hyperinsulinemia in Polycystic Ovary Syndrome
More informationPolycystic Ovary Syndrome
Polycystic Ovary Syndrome Kathleen Colleran, MD Professor of Medicine University of New Mexico HSC Presented for COMM-TC May 4, 2012 Objectives Understand the pathophysiology of PCOS Understand how to
More informationDehydroepiandrosterone-Sulfate, Insulin Resistance and Ovarian Volume Estimation in Patients With Polycystic Ovarian Syndrome
Original Article Dehydroepiandrosterone-Sulfate, Insulin Resistance and Ovarian Volume Estimation in Patients With Polycystic Ovarian Syndrome Chrysi Christodoulaki; M.D., EftihiosTrakakis; M.D.- Ph.D.,
More informationMetfornim and Pioglitazone in polycystic ovarian syndrome: A comparative study
Original Research Article Metfornim and Pioglitazone in polycystic ovarian syndrome: A comparative study Allanki Suneetha Devi 1, Jalem Anuradha 2* 1 Associate Professor, Department of Obstetrics and Gynecology,
More informationSAMPLE REPORT. Order Number: PATIENT. Age: 40 Sex: F MRN:
Patient: Age: 40 Sex: F MRN: SAMPLE PATIENT Order Number: Completed: Received: Collected: SAMPLE REPORT Progesterone ng/ml 0.34 0.95 21.00 DHEA-S mcg/dl Testosterone ng/ml 48 35 0.10 0.54 0.80 430 Sex
More informationINSULIN RESISTANCE, POLYCYSTIC OVARIAN SYNDROME An Overview
INSULIN RESISTANCE, POLYCYSTIC OVARIAN SYNDROME An Overview University of PNG School of Medicine & Health Sciences Division of Basic Medical Sciences PBL MBBS III VJ Temple 1 Insulin Resistance: What is
More informationSCHOOL OF MEDICINE AND HEALTH SCIENCES DIVISION OF BASIC MEDICAL SCIENCES DISCIPLINE OF BIOCHEMISTRY & MOLECULAR BIOLOGY
1 SCHOOL OF MEDICINE AND HEALTH SCIENCES DIVISION OF BASIC MEDICAL SCIENCES DISCIPLINE OF BIOCHEMISTRY & MOLECULAR BIOLOGY PBL SEMINAR: SEX HORMONES PART 1 An Overview What are steroid hormones? Steroid
More informationAnti-mullerian and androgens hormones in women with polycystic ovary syndrome undergoing IVF/ICSI
Iran J Reprod Med Vol. 11. No. 11. pp: 883-890, November 2013 Original article Anti-mullerian and androgens hormones in women with polycystic ovary syndrome undergoing IVF/ICSI Menha Swellam 1 Ph.D., Abeer
More informationPrevalence of Polycystic Ovarian Syndrome among urban adolescent girls and young women in Mumbai
Prevalence of Polycystic Ovarian Syndrome among urban adolescent girls and young women in Mumbai Principal Investigator Co- Investigators Consultant Collaborating Hospital Dr. Beena Joshi Dr. Srabani Mukherji
More informationClinical correlation with biochemical status in polycystic ovarian syndrome
J Obstet Gynecol India Vol. 55, No. 1 : January/February 2005 Pg 67-71 ORIGINAL ARTICLE The Journal of Obstetrics and Gynecology of India Clinical correlation with biochemical status in polycystic ovarian
More informationclinical outcome and hormone profiles before and after laparoscopic electroincision of the ovaries in women with polycystic ovary syndrome
& clinical outcome and hormone profiles before and after laparoscopic electroincision of the ovaries in women with polycystic ovary syndrome Zulfo Godinjak¹*, Ranka Javorić² 1 Gynecology and Obstetrics
More informationPrevalence of Anovulation in Subfertile Women in Kerbala 2012, A descriptive Cross-Sectional Study
Prevalence of Anovulation in Subfertile Women in Kerbala 2012, A descriptive Cross-Sectional Study Mousa Mohsen Ali* Wasan Ghazi* HayderAamerAbboud^ *Kerbala University, College of Medicine, Gynecology
More informationAbstract. Introduction. RBMOnline - Vol 10. No Reproductive BioMedicine Online; on web 15 November 2004
RBMOnline - Vol 10. No 1. 2005 100-104 Reproductive BioMedicine Online; www.rbmonline.com/article/1484 on web 15 November 2004 Article Metformin monotherapy in lean women with polycystic ovary syndrome
More informationPlasma Visfatin Concentrations in Polycystic Ovary Syndrome: Relationships with Indices of Insulin Resistance and Hyperandrogenism
Med. J. Cairo Univ., Vol. 77, No. 3, June: 1-7, 2009 www.medicaljournalofcairouniversity.com Plasma Visfatin Concentrations in Polycystic Ovary Syndrome: Relationships with Indices of Insulin Resistance
More informationSerum concentrations of carboxylated osteocalcin are increased and associated with several components of the polycystic ovarian syndrome
J Bone Miner Metab (2011) 29:201 206 DOI 10.1007/s00774-010-0211-2 ORIGINAL ARTICLE Serum concentrations of carboxylated osteocalcin are increased and associated with several components of the polycystic
More informationDiagnostic Performance of Serum Total Testosterone for Japanese Patients with Polycystic Ovary Syndrome
Endocrine Journal 2007, 54 (2), 233 238 Diagnostic Performance of Serum Total Testosterone for Japanese Patients with Polycystic Ovary Syndrome TAKESHI IWASA, TOSHIYA MATSUZAKI, MASAHIRO MINAKUCHI, NAOKO
More informationGONADAL FUNCTION: An Overview
GONADAL FUNCTION: An Overview University of PNG School of Medicine & Health Sciences Division of Basic Medical Sciences Clinical Biochemistry BMLS III & BDS IV VJ Temple 1 What are the Steroid hormones?
More informationA practical approach to the diagnosis of polycystic ovary syndrome
American Journal of Obstetrics and Gynecology (2004) 191, 713 7 www.elsevier.com/locate/ajog CLINICAL OPINION A practical approach to the diagnosis of polycystic ovary syndrome R. Jeffrey Chang, MD Department
More informationThe Severity of Menstrual Dysfunction as a Predictor of Insulin Resistance in PCOS
JCEM ONLINE Brief Report Endocrine Research The Severity of Menstrual Dysfunction as a Predictor of Insulin Resistance in PCOS Meredith Brower, Kathleen Brennan, Marita Pall, and Ricardo Azziz Department
More informationDOES INSULIN RESISTANCE CAUSE HYPERANDROGENEMIA OR HYPERANDROGENEMIA CAUSES INSULIN RESISTANCE IN PCOS
DOES INSULIN RESISTANCE CAUSE HYPERANDROGENEMIA OR HYPERANDROGENEMIA CAUSES INSULIN RESISTANCE IN PCOS D R. G A N A P A T H I. B D E P T. O F E N D O C R I N O L O G Y S T. J O H N S M E D I C A L C O
More information-INOSITOL IN LEAN WOMEN WITH THE POLYCYSTIC OVARY SYNDROME
Original Article EFFECTS OF D-CHIRO-INOSITOL IN LEAN WOMEN WITH THE POLYCYSTIC OVARY SYNDROME Maria J. Iuorno, MD, 1 Daniela J. Jakubowicz, MD, 2 Jean-Patrice Baillargeon, MD, 3 Pamela Dillon, BS, 4 Ronald
More informationDr Stella Milsom. Endocrinologist Fertility Associates Auckland. 12:30-12:40 When Puberty is PCO
Dr Stella Milsom Endocrinologist Fertility Associates Auckland 12:30-12:40 When Puberty is PCO Puberty or Polycystic Ovary Syndrome? Stella Milsom Endocrinologist Auckland DHB, University of Auckland,
More informationTHE PREVALENCE AND ETIOLOGY OF POLYCYSTIC OVARIAN SYNDROME (PCOS) AS A CAUSE OF FEMALE INFERTILITY IN CENTRAL TRAVANCORE
NSave Nature to Survive 9(1): 01-06, 2014 www.thebioscan.in THE PREVALENCE AND ETIOLOGY OF POLYCYSTIC OVARIAN SYNDROME (PCOS) AS A CAUSE OF FEMALE INFERTILITY IN CENTRAL TRAVANCORE K. ROY GEORGE AND N.
More informationReproductive Health in Non Alcoolic Fatty Liver Disease (NAFLD)
Reproductive Health in Non Alcoolic Fatty Liver Disease (NAFLD) Pr Sophie Christin-Maitre Reproductive Endocrine Unit, Hôpital Saint-Antoine, AP-HP Université Pierre et Marie Curie INSERM U933 Paris, France
More informationMetformin Therapy Decreases Hyperandrogenism and Ovarian Volume in Women with Polycystic Ovary Syndrome
IJMS Vol 36, No 2, June 2011 Original Article Metformin Therapy Decreases Hyperandrogenism and Ovarian Volume in Women with Polycystic Ovary Syndrome Marzieh Farimani Sanoee 1, Nosrat Neghab 1, Soghra
More informationReproductive outcome in women with body weight disturbances
Reproductive outcome in women with body weight disturbances Zeev Shoham M.D. Dep. Of OB/GYN Kaplan Hospital, Rehovot, Israel Weight Status BMI (kg/m 2 ) Underweight
More informationAmenorrhoea: polycystic ovary syndrome
There is so much we don't know in medicine that could make a difference, and often we focus on the big things, and the little things get forgotten. To highlight some smaller but important issues, we've
More informationFemale androgen profiles by MS for PCOS patients. CS Ho APCCMS 2010, Hong Kong 14 January 2010
Female androgen profiles by MS for PCOS patients CS Ho APCCMS 2010, Hong Kong 14 January 2010 873 women with increased serum androgens Androgen-secreting neoplasms 0.2% Classical CAH 0.6% Non-classical
More informationClinical Study Hyperandrogenism Does Not Influence Metabolic Parameters in Adolescent Girls with PCOS
International Endocrinology Volume 2012, Article ID 434830, 5 pages doi:10.1155/2012/434830 Clinical Study Hyperandrogenism Does Not Influence Metabolic Parameters in Adolescent Girls with PCOS Kim Forrester-Dumont,
More informationTreatment of hirsutism with a gonadotropin-releasing hormone agonist and estrogen replacement therapy*
Gynecology-endocrinology FERTILITY AND STERILITY Copyright 1994 The American Fertility Society Printed on acid-free paper in U S. A. Treatment of hirsutism with a gonadotropin-releasing hormone agonist
More informationFeedback inhibition of insulin secretion and insulin resistance in polycystic ovarian syndrome with and without obesity
European Review for Medical and Pharmacological Sciences 1997; 1: 17-171 Feedback inhibition of insulin secretion and insulin resistance in polycystic ovarian syndrome with and without obesity d. sinagra,
More informationSemih Tugrul, M.D., Tayfun Kutlu, M.D., Oya Pekin, M.D., Elif Baglam, M.D., H useyin Kıyak, M.D., and Ozay Oral, M.D.
Clinical, endocrine, and metabolic effects of acarbose, a a-glucosidase inhibitor, in overweight and nonoverweight patients with polycystic ovarian syndrome Semih Tugrul, M.D., Tayfun Kutlu, M.D., Oya
More informationEndocrine control of female reproductive function
Medicine School of Women s & Children s Health Discipline of Obstetrics & Gynaecology Endocrine control of female reproductive function Kirsty Walters, PhD Fertility Research Centre, School of Women s
More informationStudy of clinical presentation in cases of Polycystic Ovarian Syndrome in rural population
Original article: Study of clinical presentation in cases of Polycystic Ovarian Syndrome in rural population 1Dr Shalini Kanotra, 2 Dr Nikita Singh*, 3 Dr V B Bangal 1 Associate Professor, OBGY Department,
More informationPOLYCYSTIC OVARIAN SYNDROME Laura Tatpati, MD Reproductive Endocrinology and Infertility. Based on: ACOG No. 108 Oct 2009; reaffirmed 2015
POLYCYSTIC OVARIAN SYNDROME Laura Tatpati, MD Reproductive Endocrinology and Infertility Based on: ACOG No. 108 Oct 2009; reaffirmed 2015 NO DISCLOSURES PATIENT 26 years old presents with complaint of
More informationDiagnosis and Management of Polycystic Ovary Syndrome During Adolescence: Questions and Controversies
Diagnosis and Management of Polycystic Ovary Syndrome During Adolescence: Questions and Controversies 2017 Illinois-AACE 2017 Annual Meeting October 14, 2017 Learning Objectives 1) Understand the challenges
More informationNIH Public Access Author Manuscript Fertil Steril. Author manuscript; available in PMC 2011 April 1.
NIH Public Access Author Manuscript Published in final edited form as: Fertil Steril. 2010 April ; 93(6): 1938 1941. doi:10.1016/j.fertnstert.2008.12.138. Prevalence of Hyperandrogenemia in the Polycystic
More informationComparative study of metabolic profile of women presenting with polycystic ovary syndrome in relation to body mass index
International Journal of Reproduction, Contraception, Obstetrics and Gynecology Akshaya S et al. Int J Reprod Contracept Obstet Gynecol. 2016 Aug;5(8):2561-2565 www.ijrcog.org pissn 2320-1770 eissn 2320-1789
More informationValidation of a prediction model for the follicle-stimulating hormone response dose in women with polycystic ovary syndrome
Validation of a prediction model for the follicle-stimulating hormone response dose in women with polycystic ovary syndrome Madelon van Wely, Ph.D., a Bart C. J. M. Fauser, M.D., Ph.D., b Joop S. E. Laven,
More informationKisspeptin-54 Stimulates Gonadotropin Release Most Potently during the Preovulatory Phase of the Menstrual Cycle in Women
0021-972X/07/$15.00/0 The Journal of Clinical Endocrinology & Metabolism 92(10):3958 3966 Printed in U.S.A. Copyright 2007 by The Endocrine Society doi: 10.1210/jc.2007-1116 Kisspeptin-54 Stimulates Gonadotropin
More informationProf.Dr. Nabil Lymon Head of Internal Medicine Department
By Prof.Dr. Nabil Lymon Head of Internal Medicine Department Definitions: Hirsutism: Is the presence of terminal hair in androgendependent sites where hair does not normally grow in women. This hair growth
More informationHd Hydroxylase. Cholesterol. 17-OH Pregnenolne DHEA Andrstendiol. Pregnenolone. 17-OH Progestrone. Androstendione. Progestrone.
PATHOPHISIOLOGY OF SEX HORMONES R. Mohammadi Biochemist (Ph.D.) Faculty member of Medical Faculty CHOLESTEROL IS THE PRECURSOR OF STERIOD HORMONES Cholesterol Pregnenolone 17-OH 17βHSD Pregnenolne DHEA
More informationSCREENING OF POLYCYSTIC OVARIAN SYNDROME AMONG ADOLESCENT GIRLS AT CAIRO UNIVERSITY
SCREENING OF POLYCYSTIC OVARIAN SYNDROME AMONG ADOLESCENT GIRLS AT CAIRO UNIVERSITY Sahar Mansour Ibrahim, Yossria Ahmed Elsayed, Reda Esmail Reyad 4 and Hanan Fahmy Azzam 1* 2 3 1 Assistant Lecturer,
More informationReproductive physiology
Reproductive physiology Sex hormones: Androgens Estrogens Gestagens Learning objectives 86 (also 90) Sex Genetic sex Gonadal sex Phenotypic sex XY - XX chromosomes testes - ovaries external features Tha
More informationIMPACT OF NUTRITION ON GYNECOLOGICAL HEALTH OF FEMALE ADOLESCENTS
IMPACT OF NUTRITION ON GYNECOLOGICAL HEALTH OF FEMALE ADOLESCENTS Kedikova S. MD, PhD Medical University Sofia, Bulgaria University Hospital Maichin dom Sofia NUTRITION WHO - Nutrition is the intake of
More informationPregnancy in women with polycystic ovary syndrome: the effect of different phenotypes and features on obstetric and neonatal outcomes
Pregnancy in women with polycystic ovary syndrome: the effect of different phenotypes and features on obstetric and neonatal outcomes Stefano Palomba, M.D., a Angela Falbo, M.D., a Tiziana Russo, M.D.,
More informationAtherosclerosis 196 (2008)
Atherosclerosis 196 (2008) 958 965 The administration of estrogens, combined with anti-androgens, has beneficial effects on the hormonal features and asymmetric dimethyl-arginine levels, in women with
More informationInsulin Resistance in Infertile Sudanese Patients with Poly cystic Ovarian Syndrome (PCOS) at Laparoscopy
British Journal of Medicine & Medical Research 4(3): 889-897, 2014 SCIENCEDOMAIN international www.sciencedomain.org Insulin Resistance in Infertile Sudanese Patients with Poly cystic Ovarian Syndrome
More informationPolycystic Ovarian Syndrome and Obstructive Sleep Apnea: Poor Bedpartners. M. Begay, MD UNM Sleep Medicine Fellow 01/31/2017
Polycystic Ovarian Syndrome and Obstructive Sleep Apnea: Poor Bedpartners M. Begay, MD UNM Sleep Medicine Fellow 01/31/2017 Case of S.R. S.R. is a 39 year old female referred for suspected obstructive
More informationPCOS-Understanding the Science and Practice. Inositols. Maurizio Nordio, University Sapienza, Rome, Italy Mumbai, June 18th, 2016
PCOS-Understanding the Science and Practice Inositols Maurizio Nordio, University Sapienza, Rome, Italy Mumbai, June 18th, 2016 maurizionordio1@gmail.com PCOS and insulin It is well known that a strong
More informationPCOS. Reproductive Gynaecology and Infertility. Dr.Renda Bouzayen MD.FRCSC GREI,OBGYN Dalhousie University
Reproductive Gynaecology and Infertility PCOS Dr.Renda Bouzayen MD.FRCSC GREI,OBGYN Dalhousie University Dr.Hussein Sabban MD. FRCSC PGY6 GREI Dalhousie University Disclosure No conflict of interest Pilot
More informationReproductive Health and Pituitary Disease
Reproductive Health and Pituitary Disease Janet F. McLaren, MD Assistant Professor Division of Reproductive Endocrinology and Infertility Department of Obstetrics and Gynecology jmclaren@uabmc.edu Objectives
More information